Dr. Robert Bentley Brings a New Skin Cancer Treatment to West Alabama

Dr. Robert Bentley Brings New Skin Cancer Treatment to West Alabama

West Alabama now has access to a non-invasive cancer treatment for non-melanoma skin cancer, the most common cancer in humans. Dr. Robert Bentley has teamed with Skin Cure Oncology to deliver low-dose radiation treatments for skin cancer using Superficial Radiation Treatment (SRT) for patients.

“We diagnose and treat a high amount of non-melanoma skin cancers at our practice,” said Dr. Bentley. “We are so pleased we now can offer this treatment for our patients as an alternative to surgery.” The SRT delivers precise, low dose radiation that only goes skin deep to safely destroy cancer without damaging healthy tissue. Unlike Mohs Surgery, the surgical option for treating skin cancers, there is no cutting or stitching or plastic surgery needed to repair scars. “Before SRT, patient’s only option was to have to surgery, but now they have an option if the patient doesn’t want to have surgery again, or if they have issues that may prevent them from having surgery,” Dr. Bentley said.

Because of the low-dose of radiation delivered, the treatment is performed at Dr. Bentley’s medical practice, Dermatology Care of Alabama, by a Radiation Therapist. Chris Hannon has been a radiation therapist for 26 years working in north Alabama, South Carolina and Texas and recently joined Dermatology Care of Alabama, working with SkinCure Oncology to treat the patients Dr. Bentley refers for the in-office cancer radiation treatment.

Non-melanoma skin cancer can also be treated through hospitals and cancer treatment center that utilize linear accelerators. Unlike SRT, linear accelerators are built to deliver more powerful radiation throughout the body.

With SRT, the radiation only reaches six millimeters, the depth of the skin. All of the SRT radiation goes to the skin, treating the targeted lesion, nothing internally is affected. Typically squamous cell or basal cell carcinomas require 20 treatments, which is about three per week for patients.

SRT has about a 95 percent cure rate.

With this new modality